Expert InterviewKelonia Therapeutics
Slingshot members are talking to an expert! The topic is:
A Look at the Phase 1 Data from Kelonia’s inMMyCAR study Evaluating KLN-1010, an Investigational in vivo BCMA-Directed CAR-T therapy in Patients with Relapsed/refractory Multiple Myeloma
Executed on:Apr 29, 2026 4:00 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
Interview Goal
To understand physician perspectives on the Phase 1 inMMyCAR data evaluating KLN-1010 from Kelonia Therapeutics, an investigational in vivo BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, including interpretation of early safety, efficacy, feasibility, and how an in vivo CAR-T approach may compare with ex vivo CAR-T and other BCMA-targeted therapies.